Afya Limited (A2FY34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 29.00 |
|---|---|
| 52-week range | 27.29 – 43.40 |
| Return, 1 month / 3 months | −14.5% / −20.6% |
| Return, 1 year / 3 years | −22.3% / −24.0% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 55.4% |
| Worst drawdown (1 year) | -31.7% |
| Average daily value traded | 0.14M BRL |
| Dividend yield | 5.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Afya Limited is a Brazilian education company focused on medical and health sciences. It runs medical schools and offers undergraduate programs for future physicians, along with continuing education and digital courses for health professionals. Its students and customers are mainly aspiring doctors and practising health workers in Brazil, and the company is based in that country. Afya combines classroom teaching at its schools with online learning tools and services that support medical education and clinical practice.
Afya Limited is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code A2FY34, with its price quoted in Brazilian reais (BRL). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Afya Limited (A2FY34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 29.00 on 27 October 2026.
Its price-based Market X-Ray is 31 out of 100 (a weak price profile), ranking 1,190 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 22.3% and over the last three months it fell 20.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 22 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.7% | ||
| From 52-week high | -33.2% | ||
| Momentum | 18 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -20.6% | ||
| 6-month return | -15.9% | ||
| 12-month return, skipping the last month | -9.2% | ||
| Stability (higher is calmer) | 35 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 55.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -31.7% | ||
| Liquidity | 61 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.14M BRL | ||
| Zero-volume days | 1.7% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 5.8% | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −23.7% |
|---|---|
| 1 month | −14.5% |
| 3 months | −20.6% |
| 6 months | −15.9% |
| 1 year | −22.3% |
| 3 years | −24.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 35.64 / 36.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.15 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Mar 2026 | BRL 1.6943 |
| 25 Mar 2025 | BRL 0.6830 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.